02.02.2022

NeoPhore achieves scientific milestones

We are pleased to announce that NeoPhore recently achieved all of its investment related scientific milestones, enabling the contingent second completion funding of £9.4m to be issued from the previously reported series B investment round. The financing will be used to further progress NeoPhore’s lead compounds from drug discovery programs targeting the DNA mismatch repair pathway.

More news

28.07.2022

NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center

Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a t…

18.02.2022

St George’s expands successful collaboration in pursuit of new, first-in-class cancer therapies

St George’s, University of London and NeoPhore today announce the expansion of their research partnership after a successful collaboration i…

11.10.2021

Additional Series B funding announcement

We are delighted to announce that additional Series B funding has been agreed, with the members of Italian Angels for Growth and Club degli…

Contact us at info@neophore.com  |  
Call us +44 (0) 330 128 9990